MR spectroscopy of metabolic disorders

Neuroimaging Clinics of North America

Volumn 16, Issue 1, 2006, Pages 87-116

  Cecil, Kim M ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEXANDER DISEASE; AMINO ACID METABOLISM; ARTICLE; DISORDERS OF PEROXISOMAL FUNCTIONS; ENZYME DEFICIENCY; GENETIC CORRELATION; HUMAN; INBORN ERROR OF METABOLISM; METABOLIC DISORDER; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; X CHROMOSOME LINKED DISORDER;

EID: 33644927546     PISSN: 10525149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nic.2005.10.004     Document Type: Review

References (171)

1. A.J. Barkovich Pediatric neuroimaging 2005 Lippincott Williams & Wilkins Philadelphia
2. W.S. Ball, B.V. Jones, and K.M. Cecil Metabolic and neurodegenerative disease in children R.E. Latchaw J. Kucharczyk M.E. Moseley Diagnostic and therapeutic imaging of the nervous system 2005 Elsevier Mosby Philadelphia 1283 1320
3. O. Gonen, A.K. Viswanathan, and I. Catalaa Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy Magn Reson Med 40 5 1998 684 689
4. S.H. Moolenaar, U.F. Engelke, and R.A. Wevers Proton nuclear magnetic resonance spectroscopy of body fluids in the field of inborn errors of metabolism Ann Clin Biochem 40 Pt 1 2003 16 24
5. S.H. Moolenaar, M.S. van der Knaap, and U.F. Engelke In vivo and in vitro NMR spectroscopy reveal a putative novel inborn error involving polyol metabolism NMR Biomed 14 3 2001 167 176
6. T. Varho, M. Komu, and P. Sonninen A new metabolite contributing to N-acetyl signal in 1H MRS of the brain in Salla disease Neurology 52 8 1999 1668 1672
7. T. Mano, J. Ono, and T. Kaminaga Proton MR spectroscopy of Sjogren-Larsson's syndrome AJNR Am J Neuroradiol 20 9 1999 1671 1673
8. M.A. Willemsen, M.A. Lutt, and P.M. Steijlen Clinical and biochemical effects of zileuton in patients with the Sjogren-Larsson syndrome Eur J Pediatr 160 12 2001 711 717
9. T. Kaminaga, T. Mano, and J. Ono Proton magnetic resonance spectroscopy of Sjogren-Larsson syndrome heterozygotes Magn Reson Med 45 6 2001 1112 1115
10. S.L. Vanhanen, J. Puranen, and T. Autti Neuroradiological findings (MRS, MRI, SPECT) in infantile neuronal ceroid-lipofuscinosis (infantile CLN1) at different stages of the disease Neuropediatrics 35 1 2004 27 35
11. B. Sitter, T. Autti, and J. Tyynela High-resolution magic angle spinning and 1H magnetic resonance spectroscopy reveal significantly altered neuronal metabolite profiles in CLN1 but not in CLN3 J Neurosci Res 77 5 2004 762 769
12. N. De Stefano, M.T. Dotti, and M. Mortilla Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis Brain 124 Pt 1 2001 121 131
13. M. Sylvain, D.L. Arnold, and C.R. Scriver Magnetic resonance spectroscopy in Niemann-Pick disease type C: correlation with diagnosis and clinical response to cholestyramine and lovastatin Pediatr Neurol 10 3 1994 228 232
14. G. Tedeschi, S. Bonavita, and N.W. Barton Proton magnetic resonance spectroscopic imaging in the clinical evaluation of patients with Niemann-Pick type C disease J Neurol Neurosurg Psychiatry 65 1 1998 72 79
15. Y. Takahashi, K. Sukegawa, and M. Aoki Evaluation of accumulated mucopolysaccharides in the brain of patients with mucopolysaccharidoses by (1)H-magnetic resonance spectroscopy before and after bone marrow transplantation Pediatr Res 49 3 2001 349 355
16. B. Kruse, F. Hanefeld, and H.J. Christen Alterations of brain metabolites in metachromatic leukodystrophy as detected by localized proton magnetic resonance spectroscopy in vivo J Neurol 241 2 1993 68 74
17. K. Brockmann, P. Dechent, and B. Wilken Proton MRS profile of cerebral metabolic abnormalities in Krabbe disease Neurology 60 5 2003 819 825
18. M.K. Zarifi, A.A. Tzika, and L.G. Astrakas Magnetic resonance spectroscopy and magnetic resonance imaging findings in Krabbe's disease J Child Neurol 16 7 2001 522 526
19. A. Alkan, R. Kutlu, and C. Yakinci Infantile Sandhoff's disease: multivoxel magnetic resonance spectroscopy findings J Child Neurol 18 6 2003 425 428
20. D. Seitz, W. Grodd, and A. Schwab MR imaging and localized proton MR spectroscopy in late infantile neuronal ceroid lipofuscinosis AJNR Am J Neuroradiol 19 7 1998 1373 1377
21. K. Brockmann, P.J. Pouwels, and H.J. Christen Localized proton magnetic resonance spectroscopy of cerebral metabolic disturbances in children with neuronal ceroid lipofuscinosis Neuropediatrics 27 5 1996 242 248
22. S. Confort-Gouny, B. Chabrol, and J. Vion-Dury MRI and localized proton MRS in early infantile form of neuronal ceroid-lipofuscinosis Pediatr Neurol 9 1 1993 57 60
23. L. Lauronen, P.B. Munroe, and I. Jarvela Delayed classic and protracted phenotypes of compound heterozygous juvenile neuronal ceroid lipofuscinosis Neurology 52 2 1999 360 365
24. 31Phosphorus magnetic resonance spectroscopy in late-onset Tay-Sachs disease J Child Neurol 16 5 2001 377 380
25. M. Hochuli, K. Wuthrich, and B. Steinmann Two-dimensional NMR spectroscopy of urinary glycosaminoglycans from patients with different mucopolysaccharidoses NMR Biomed 16 4 2003 224 236
26. U.F. Engelke, M.L. Liebrand-van Sambeek, and J.G. de Jong N-acetylated metabolites in urine: proton nuclear magnetic resonance spectroscopic study on patients with inborn errors of metabolism Clin Chem 50 1 2004 58 66
27. H. Bruhn, B. Kruse, and G.C. Korenke Proton NMR spectroscopy of cerebral metabolic alterations in infantile peroxisomal disorders J Comput Assist Tomogr 16 3 1992 335 344
28. A. Viola, S. Confort-Gouny, and J.P. Ranjeva MR imaging and MR spectroscopy in rhizomelic chondrodysplasia punctata AJNR Am J Neuroradiol 23 3 2002 480 483
29. A. Alkan, R. Kutlu, and C. Yakinci Delayed myelination in a rhizomelic chondrodysplasia punctata case: MR spectroscopy findings Magn Reson Imaging 21 1 2003 77 80
30. R. Srinivasan, D. Vigneron, and N. Sailasuta A comparative study of myo-inositol quantification using LC model at 1.5 T and 3.0 T with 3 D 1H proton spectroscopic imaging of the human brain Magn Reson Imaging 22 4 2004 523 528
31. H.W. Moser, and P.B. Barker Magnetic resonance spectroscopy: a new guide for the therapy of adrenoleukodystrophy Neurology 64 3 2005 406 407
32. G. Oz, I. Tkac, and L.R. Charnas Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients Neurology 64 3 2005 434 441
33. B. Wilken, P. Dechent, and K. Brockmann Quantitative proton magnetic resonance spectroscopy of children with adrenoleukodystrophy before and after hematopoietic stem cell transplantation Neuropediatrics 34 5 2003 237 246
34. F.S. Eichler, R. Itoh, and P.B. Barker Proton MR spectroscopic and diffusion tensor brain MR imaging in X-linked adrenoleukodystrophy: initial experience Radiology 225 1 2002 245 252
35. F.S. Eichler, P.B. Barker, and C. Cox Proton MR spectroscopic imaging predicts lesion progression on MRI in X-linked adrenoleukodystrophy Neurology 58 6 2002 901 907
36. M. Izquierdo, C. Adamsbaum, and A. Benosman MR spectroscopic imaging of normal-appearing white matter in adrenoleukodystrophy Pediatr Radiol 30 9 2000 621 629
37. A.M. Salvan, S. Confort-Gouny, and B. Chabrol Brain metabolic impairment in non-cerebral and cerebral forms of X-linked adrenoleukodystrophy by proton MRS: identification of metabolic patterns by discriminant analysis Magn Reson Med 41 6 1999 1119 1126
38. P.J. Pouwels, B. Kruse, and G.C. Korenke Quantitative proton magnetic resonance spectroscopy of childhood adrenoleukodystrophy Neuropediatrics 29 5 1998 254 264
39. V. Rajanayagam, M. Balthazor, and E.G. Shapiro Proton MR spectroscopy and neuropsychological testing in adrenoleukodystrophy AJNR Am J Neuroradiol 18 10 1997 1909 1914
40. A. Tourbah, J.L. Stievenart, and M.T. Iba-Zizen Localized proton magnetic resonance spectroscopy in patients with adult adrenoleukodystrophy. Increase of choline compounds in normal appearing white matter Arch Neurol 54 5 1997 586 592
41. G.C. Korenke, P.J. Pouwels, and J. Frahm Arrested cerebral adrenoleukodystrophy: a clinical and proton magnetic resonance spectroscopy study in three patients Pediatr Neurol 15 2 1996 103 107
42. V. Rajanayagam, J. Grad, and W. Krivit Proton MR spectroscopy of childhood adrenoleukodystrophy AJNR Am J Neuroradiol 17 6 1996 1013 1024
43. S. Confort-Gouny, J. Vion-Dury, and B. Chabrol Localised proton magnetic resonance spectroscopy in X-linked adrenoleukodystrophy Neuroradiology 37 7 1995 568 575
44. B. Kruse, P.B. Barker, and P.C. van Zijl Multislice proton magnetic resonance spectroscopic imaging in X-linked adrenoleukodystrophy Ann Neurol 36 4 1994 595 608
45. A.A. Tzika, W.S. Ball Jr, and D.B. Vigneron Childhood adrenoleukodystrophy: assessment with proton MR spectroscopy Radiology 189 2 1993 467 480
46. M.C. Bianchi, M. Tosetti, and R. Battini Proton MR spectroscopy of mitochondrial diseases: analysis of brain metabolic abnormalities and their possible diagnostic relevance AJNR Am J Neuroradiol 24 10 2003 1958 1966
47. I. Krageloh-Mann, W. Grodd, and M. Schoning Proton spectroscopy in five patients with Leigh's disease and mitochondrial enzyme deficiency Dev Med Child Neurol 35 9 1993 769 776
48. J.A. Detre, Z.Y. Wang, and A.R. Bogdan Regional variation in brain lactate in Leigh syndrome by localized 1H magnetic resonance spectroscopy Ann Neurol 29 2 1991 218 221
49. J.H. Cross, A. Connelly, and D.G. Gadian Clinical diversity of pyruvate dehydrogenase deficiency Pediatr Neurol 10 4 1994 276 283
50. M.I. Shevell, P.M. Matthews, and C.R. Scriver Cerebral dysgenesis and lactic acidemia: an MRI/MRS phenotype associated with pyruvate dehydrogenase deficiency Pediatr Neurol 11 3 1994 224 229
51. B. Kruse, F. Hanefeld, and U. Holzbach Proton spectroscopy in patients with Leigh's disease and mitochondrial enzyme deficiency Dev Med Child Neurol 36 9 1994 839 843
52. D.J. Zand, E.M. Simon, and S.B. Pulitzer In vivo pyruvate detected by MR spectroscopy in neonatal pyruvate dehydrogenase deficiency AJNR Am J Neuroradiol 24 7 2003 1471 1474
53. M.E. Rubio-Gozalbo, A. Heerschap, and J.M. Trijbels Proton MR spectroscopy in a child with pyruvate dehydrogenase complex deficiency Magn Reson Imaging 17 6 1999 939 944
54. S. Kimura, N. Ohtuki, and A. Nezu Clinical and radiologic improvements in mitochondrial encephalomyelopathy following sodium dichloroacetate therapy Brain Dev 19 8 1997 535 540
55. M. Harada, M. Tanouchi, and K. Arai Therapeutic efficacy of a case of pyruvate dehydrogenase complex deficiency monitored by localized proton magnetic resonance spectroscopy Magn Reson Imaging 14 1 1996 129 133
56. J. Takanashi, K. Sugita, and Y. Tanabe Dichloroacetate treatment in Leigh syndrome caused by mitochondrial DNA mutation J Neurol Sci 145 1 1997 83 86
57. N. Barisic, G. Bernert, and O. Ipsiroglu Effects of oral creatine supplementation in a patient with MELAS phenotype and associated nephropathy Neuropediatrics 33 3 2002 157 161
58. H.E. Moller, D. Wiedermann, and G. Kurlemann Application of NMR spectroscopy to monitoring MELAS treatment: a case report Muscle Nerve 25 4 2002 593 600
59. K. Kamada, F. Takeuchi, and K. Houkin Reversible brain dysfunction in MELAS, MEG, and (1)H MRS analysis J Neurol Neurosurg Psychiatry 70 5 2001 675 678
60. H.S. Kim, D.I. Kim, and B.I. Lee Diffusion-weighted image and MR spectroscopic analysis of a case of MELAS with repeated attacks Yonsei Med J 42 1 2001 128 133
61. F. Dubeau, N. De Stefano, and B.G. Zifkin Oxidative phosphorylation defect in the brains of carriers of the tRNAleu(UUR) A3243G mutation in a MELAS pedigree Ann Neurol 47 2 2000 179 185
62. E. Wilichowski, P.J. Pouwels, and J. Frahm Quantitative proton magnetic resonance spectroscopy of cerebral metabolic disturbances in patients with MELAS Neuropediatrics 30 5 1999 256 263
63. S.G. Pavlakis, P.B. Kingsley, and G.P. Kaplan Magnetic resonance spectroscopy: use in monitoring MELAS treatment Arch Neurol 55 6 1998 849 852
64. P.M. Matthews, and T. Taivassalo Applications of magnetic resonance spectroscopy to diagnosis and monitoring of mitochondrial disease Ital J Neurol Sci 18 6 1997 341 351
65. J.M. Clark, M.P. Marks, and E. Adalsteinsson MELAS: clinical and pathologic correlations with MRI, xenon/CT, and MR spectroscopy Neurology 46 1 1996 223 227
66. N. De Stefano, P.M. Matthews, and D.L. Arnold Reversible decreases in N-acetylaspartate after acute brain injury Magn Reson Med 34 5 1995 721 727
67. M. Castillo, L. Kwock, and C. Green MELAS syndrome: imaging and proton MR spectroscopic findings AJNR Am J Neuroradiol 16 2 1995 233 239
68. P.M. Mathews, F. Andermann, and K. Silver Proton MR spectroscopic characterization of differences in regional brain metabolic abnormalities in mitochondrial encephalomyopathies Neurology 43 12 1993 2484 2490
69. A.J. Barkovich, W.V. Good, and T.K. Koch Mitochondrial disorders: analysis of their clinical and imaging characteristics AJNR Am J Neuroradiol 14 5 1993 1119 1137
70. 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin Neurology 42 11 1992 2147 2152
71. P. Kaufmann, D.C. Shungu, and M.C. Sano Cerebral lactic acidosis correlates with neurological impairment in MELAS Neurology 62 8 2004 1297 1302
72. A. Dinopoulos, K.M. Cecil, and M.B. Schapiro Brain MRI and proton MRS findings in infants and children with respiratory chain defects Neuropediatrics 36 5 2005 290 301
73. J. Star-Lack, D. Spielman, and E. Adalsteinsson In vivo lactate editing with simultaneous detection of choline, creatine, NAA, and lipid singlets at 1.5 T using PRESS excitation with applications to the study of brain and head and neck tumors J Magn Reson 133 2 1998 243 254
74. K. Brockmann, P. Dechent, and M. Meins Cerebral proton magnetic resonance spectroscopy in infantile Alexander disease J Neurol 250 3 2003 300 306
75. 1H-MR spectroscopy in a case of juvenile Alexander disease Brain Dev 24 7 2002 723 726
76. J. Takanashi, K. Sugita, and Y. Tanabe Adolescent case of Alexander disease: MR imaging and MR spectroscopy Pediatr Neurol 18 1 1998 67 70
77. 13C NMR spectra of N-acetylaspartylglutamate and its detection in urine from patients with Canavan disease J Pharm Biomed Anal 31 3 2003 455 463
78. C. Janson, S. McPhee, and L. Bilaniuk Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain Hum Gene Ther 13 11 2002 1391 1412
79. I. Harting, and A. Seitz [Canavan disease] Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 173 10 2001 M275 M276
80. N. Gordon Canavan disease: a review of recent developments Eur J Paediatr Neurol 5 2 2001 65 69
81. A. Moreno, B.D. Ross, and S. Bluml Direct determination of the N-acetyl-L-aspartate synthesis rate in the human brain by (13)C MRS and [1-(13)C]glucose infusion J Neurochem 77 1 2001 347 350
82. S. Bluml, A. Moreno, and J.H. Hwang 1-(13)C glucose magnetic resonance spectroscopy of pediatric and adult brain disorders NMR Biomed 14 1 2001 19 32
83. R. Matalon, P.L. Rady, and K.A. Platt Knock-out mouse for Canavan disease: a model for gene transfer to the central nervous system J Gene Med 2 3 2000 165 175
84. N. Aydinli, M. Caliskan, and M. Calay Use of localized proton nuclear magnetic resonance spectroscopy in Canavan's disease Turk J Pediatr 40 4 1998 549 557
85. 13C MRS at 1.5 T J Magn Reson 136 2 1999 219 225
86. K.W. Gripp, R.A. Zimmerman, and Z.J. Wang Imaging studies in a unique familial dysmyelinating disorder AJNR Am J Neuroradiol 19 7 1998 1368 1372
87. H.J. Wittsack, H. Kugel, and B. Roth Quantitative measurements with localized 1H MR spectroscopy in children with Canavan's disease J Magn Reson Imaging 6 6 1996 889 893
88. V. Engelbrecht, M. Rassek, and J. Gartner [Magnetic resonance tomography and localized proton spectroscopy in 2 siblings with Canavan's disease] Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 163 3 1995 238 244
89. R.A. Wevers, U. Engelke, and U. Wendel Standardized method for high-resolution 1H-NMR of cerebrospinal fluid Clin Chem 41 5 1995 744 751
90. P.B. Toft, R. Geiss-Holtorff, and M.O. Rolland Magnetic resonance imaging in juvenile Canavan disease Eur J Pediatr 152 9 1993 750 753
91. W. Grodd, I. Krageloh-Mann, and U. Klose Metabolic and destructive brain disorders in children: findings with localized proton MR spectroscopy Radiology 181 1 1991 173 181
92. M.S. van der Knaap, P. van der Voorn, and F. Barkhof A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate Ann Neurol 53 2 2003 252 258
93. M.S. van der Knaap, P.G. Barth, and F.J. Gabreels A new leukoencephalopathy with vanishing white matter Neurology 48 4 1997 845 855
94. M.S. van der Knaap, W. Kamphorst, and P.G. Barth Phenotypic variation in leukoencephalopathy with vanishing white matter Neurology 51 2 1998 540 547
95. M.S. van der Knaap, R.A. Wevers, and S. Kure Increased cerebrospinal fluid glycine: a biochemical marker for a leukoencephalopathy with vanishing white matter J Child Neurol 14 11 1999 728 731
96. M.S. van der Knaap, S. Naidu, and P.J. Pouwels New syndrome characterized by hypomyelination with atrophy of the basal ganglia and cerebellum AJNR Am J Neuroradiol 23 9 2002 1466 1474
97. B. Plecko, S. Stockler-Ipsiroglu, and S. Gruber Degree of hypomyelination and magnetic resonance spectroscopy findings in patients with Pelizaeus Merzbacher phenotype Neuropediatrics 34 3 2003 127 136
98. M.S. van der Knaap, R.A. Wevers, and E.A. Struys Leukoencephalopathy associated with a disturbance in the metabolism of polyols Ann Neurol 46 6 1999 925 928
99. M.S. van der Knaap, J. Valk, and P.G. Barth Leukoencephalopathy with swelling in children and adolescents: MRI patterns and differential diagnosis Neuroradiology 37 8 1995 679 686
100. M.S. van der Knaap, P.G. Barth, and H. Stroink Leukoencephalopathy with swelling and a discrepantly mild clinical course in eight children Ann Neurol 37 3 1995 324 334
101. H.E. Moller, J. Weglage, and U. Bick Brain imaging and proton magnetic resonance spectroscopy in patients with phenylketonuria Pediatrics 112 6 Pt 2 2003 1580 1583
102. R.A. Moats, K.D. Moseley, and R. Koch Brain phenylalanine concentrations in phenylketonuria: research and treatment of adults Pediatrics 112 6 Pt 2 2003 1575 1579
103. R. Matalon, S. Surendran, and K.M. Matalon Future role of large neutral amino acids in transport of phenylalanine into the brain Pediatrics 112 6 Pt 2 2003 1570 1574
104. 31P MR spectroscopy Pediatr Res 53 4 2003 654 662
105. J. Weglage, D. Wiedermann, and J. Denecke Individual blood-brain barrier phenylalanine transport in siblings with classical phenylketonuria J Inherit Metab Dis 25 6 2002 431 436
106. R. Koch, B. Burton, and G. Hoganson Phenylketonuria in adulthood: a collaborative study J Inherit Metab Dis 25 5 2002 333 346
107. Y.H. Chien, S.F. Peng, and T.R. Wang Cranial MR spectroscopy of tetrahydrobiopterin deficiency AJNR Am J Neuroradiol 23 6 2002 1055 1058
108. J. Weglage, D. Wiedermann, and J. Denecke Individual blood-brain barrier phenylalanine transport determines clinical outcome in phenylketonuria Ann Neurol 50 4 2001 463 467
109. M. Dezortova, M. Hajek, and J. Tintera MR in phenylketonuria-related brain lesions Acta Radiol 42 5 2001 459 466
110. A. Rupp, R. Kreis, and J. Zschocke Variability of blood-brain ratios of phenylalanine in typical patients with phenylketonuria J Cereb Blood Flow Metab 21 3 2001 276 284
111. J. Weglage, M. Pietsch, and R. Feldmann Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia Pediatr Res 49 4 2001 532 536
112. R. Kreis Comments on in vivo proton magnetic resonance spectroscopy in phenylketonuria Eur J Pediatr 159 Suppl 2 2000 S126 S128
113. R. Koch, R. Moats, and F. Guttler Blood-brain phenylalanine relationships in persons with phenylketonuria Pediatrics 106 5 2000 1093 1096
114. F.K. Trefz, S. Cipcic-Schmidt, and R. Koch Final intelligence in late treated patients with phenylketonuria Eur J Pediatr 159 Suppl 2 2000 S145 S148
115. H.E. Moller, K. Ullrich, and J. Weglage In vivo proton magnetic resonance spectroscopy in phenylketonuria Eur J Pediatr 159 Suppl 2 2000 S121 S125
116. D.P. Brenton, and J. Pietz Adult care in phenylketonuria and hyperphenylalaninaemia: the relevance of neurological abnormalities Eur J Pediatr 159 Suppl 2 2000 S114 S120
117. V. Leuzzi, M.C. Bianchi, and M. Tosetti Clinical significance of brain phenylalanine concentration assessed by in vivo proton magnetic resonance spectroscopy in phenylketonuria J Inherit Metab Dis 23 6 2000 563 570
118. J. Pietz, R. Kreis, and A. Rupp Large neutral amino acids block phenylalanine transport into brain tissue in patients with phenylketonuria J Clin Invest 103 8 1999 1169 1178
119. H.E. Moller, J. Weglage, and D. Wiedermann Blood-brain barrier phenylalanine transport and individual vulnerability in phenylketonuria J Cereb Blood Flow Metab 18 11 1998 1184 1191
120. J. Weglage, H.E. Moller, and D. Wiedermann In vivo NMR spectroscopy in patients with phenylketonuria: clinical significance of interindividual differences in brain phenylalanine concentrations J Inherit Metab Dis 21 1 1998 81 82
121. H.E. Moller, J. Weglage, and D. Wiedermann Kinetics of phenylalanine transport at the human blood-brain barrier investigated in vivo Brain Res 778 2 1997 329 337
122. J. Pietz, R. Kreis, and H. Schmidt Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment Radiology 201 2 1996 413 420
123. M. Dezortova, L. Hejcmanova, and M. Hajek Decreasing choline signal-a marker of phenylketonuria? MAGMA 4 3-4 1996 181 186
124. 1H magnetic resonance spectroscopy Pediatr Res 38 5 1995 657 663
125. H.E. Moller, P. Vermathen, and K. Ullrich In-vivo NMR spectroscopy in patients with phenylketonuria: changes of cerebral phenylalanine levels under dietary treatment Neuropediatrics 26 4 1995 199 202
126. 1H magnetic-resonance spectroscopy J Magn Reson B 107 3 1995 242 251
127. E.J. Novotny Jr, M.J. Avison, and N. Herschkowitz In vivo measurement of phenylalanine in human brain by proton nuclear magnetic resonance spectroscopy Pediatr Res 37 2 1995 244 249
128. K. Johannik, P. Van Hecke, and B. Francois Localized brain proton NMR spectroscopy in young adult phenylketonuria patients Magn Reson Med 31 1 1994 53 57
129. U. Bick, K. Ullrich, and U. Stober White matter abnormalities in patients with treated hyperphenylalaninaemia: magnetic resonance relaxometry and proton spectroscopy findings Eur J Pediatr 152 12 1993 1012 1020
130. M. Hajek, L. Hejcmanova, and J. Pradny Proton in vivo spectroscopy of patients with hyperphenylalaninaemia Neuropediatrics 24 2 1993 111 112
131. A. Viola, B. Chabrol, and F. Nicoli Magnetic resonance spectroscopy study of glycine pathways in nonketotic hyperglycinemia Pediatr Res 52 2 2002 292 300
132. T.A. Huisman, T. Thiel, and B. Steinmann Proton magnetic resonance spectroscopy of the brain of a neonate with nonketotic hyperglycinemia: in vivo-in vitro (ex vivo) correlation Eur Radiol 12 4 2002 858 861
133. C.G. Choi, H.K. Lee, and J.H. Yoon Localized proton MR spectroscopic detection of nonketotic hyperglycinemia in an infant Korean J Radiol 2 4 2001 239 242
134. Y. Suzuki, H. Ueda, and Y. Toribe [Proton MR spectroscopy of nonketotic hyperglycinemia] No To Hattatsu 33 5 2001 422 425
135. 1H magnetic resonance spectroscopic measurement of brain glycine levels in nonketotic hyperglycinemia J Neuroimaging 11 2 2001 209 211
136. W. Heindel, H. Kugel, and B. Roth Noninvasive detection of increased glycine content by proton MR spectroscopy in the brains of two infants with nonketotic hyperglycinemia AJNR Am J Neuroradiol 14 3 1993 629 635
137. W. Jan, R.A. Zimmerman, and Z.J. Wang MR diffusion imaging and MR spectroscopy of maple syrup urine disease during acute metabolic decompensation Neuroradiology 45 6 2003 393 399
138. 1H NMR spectroscopy characterisation of the complex metabolic pattern of urine from patients with inborn errors of metabolism: 2-hydroxyglutaric aciduria and maple syrup urine disease J Pharm Biomed Anal 15 11 1997 1647 1659
139. W. Heindel, H. Kugel, and U. Wendel Proton magnetic resonance spectroscopy reflects metabolic decompensation in maple syrup urine disease Pediatr Radiol 25 4 1995 296 299
140. S.R. Felber, W. Sperl, and A. Chemelli Maple syrup urine disease: metabolic decompensation monitored by proton magnetic resonance imaging and spectroscopy Ann Neurol 33 4 1993 396 401
141. S.W. Provencher Estimation of metabolite concentrations from localized in vivo proton NMR spectra Magn Reson Med 30 6 1993 672 679
142. 1H-NMR studies of urine in propionic acidemia and methylmalonic acidemia Acta Paediatr Jpn 33 2 1991 139 145
143. S.E. Davies, R.A. Iles, and T.E. Stacey Creatine metabolism during metabolic perturbations in patients with organic acidurias Clin Chim Acta 194 2-3 1990 203 217
144. R.A. Iles, R.A. Chalmers, and A.J. Hind Methylmalonic aciduria and propionic acidaemia studied by proton nuclear magnetic resonance spectroscopy Clin Chim Acta 161 2 1986 173 189
145. R.A. Iles, A.J. Hind, and R.A. Chalmers Use of proton nuclear magnetic resonance spectroscopy in detection and study of organic acidurias Clin Chem 31 11 1985 1795 1801
146. M. Takeuchi, M. Harada, and K. Matsuzaki Magnetic resonance imaging and spectroscopy in a patient with treated methylmalonic acidemia J Comput Assist Tomogr 27 4 2003 547 551
147. B.C. Trinh, E.R. Melhem, and P.B. Barker Multi-slice proton MR spectroscopy and diffusion-weighted imaging in methylmalonic acidemia: report of two cases and review of the literature AJNR Am J Neuroradiol 22 5 2001 831 833
148. A.P. Chemelli, M. Schocke, and W. Sperl Magnetic resonance spectroscopy (MRS) in five patients with treated propionic acidemia J Magn Reson Imaging 11 6 2000 596 600
149. 1H MR spectroscopy of the basal ganglia in childhood: a semiquantitative analysis Neuroradiology 40 5 1998 315 323
150. S.P. Burns, R.A. Iles, and J.M. Saudubray Propionylcarnitine excretion is not affected by metronidazole administration to patients with disorders of propionate metabolism Eur J Pediatr 155 1 1996 31 35
151. A.J. Bergman, M.S. Van der Knaap, and J.A. Smeitink Magnetic resonance imaging and spectroscopy of the brain in propionic acidemia: clinical and biochemical considerations Pediatr Res 40 3 1996 404 409
152. S. Kurul, H. Cakmakci, and E. Dirik Glutaric aciduria type 1: proton magnetic resonance spectroscopy findings Pediatr Neurol 31 3 2004 228 231
153. M.A. al-Essa, M.S. Rashed, and S.M. Bakheet Glutaric aciduria type II: observations in seven patients with neonatal- and late-onset disease J Perinatol 20 2 2000 120 128
154. F. Hanefeld, B. Kruse, and H. Bruhn In vivo proton magnetic resonance spectroscopy of the brain in a patient with L-2-hydroxyglutaric acidemia Pediatr Res 35 5 1994 614 616
155. K. Aydin, M. Ozmen, and B. Tatli Single-voxel MR spectroscopy and diffusion-weighted MRI in two patients with l-2-hydroxyglutaric aciduria Pediatr Radiol 33 12 2003 872 876
156. R. Jayasundar, A.K. Sahani, and S. Gaikwad Proton MR spectroscopy of basal ganglia in Wilson's disease: case report and review of literature Magn Reson Imaging 20 1 2002 131 135
157. A. Alanen, M. Komu, and M. Penttinen Magnetic resonance imaging and proton MR spectroscopy in Wilson's disease Br J Radiol 72 860 1999 749 756
158. E. Kraft, C. Trenkwalder, and F. Then Bergh Magnetic resonance proton spectroscopy of the brain in Wilson's disease J Neurol 246 8 1999 693 699
159. Z.I. Wang, G.T. Berry, and S.F. Dreha Proton magnetic resonance spectroscopy of brain metabolites in galactosemia Ann Neurol 50 2 2001 266 269
160. G.T. Berry, J.V. Hunter, and Z. Wang In vivo evidence of brain galactitol accumulation in an infant with galactosemia and encephalopathy J Pediatr 138 2 2001 260 262
161. V. Ganesan, A. Johnson, and A. Connelly Guanidinoacetate methyltransferase deficiency: new clinical features Pediatr Neurol 17 2 1997 155 157
162. G.S. Salomons, S.J. van Dooren, and N.M. Verhoeven X-linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome Am J Hum Genet 68 6 2001 1497 1500
163. K.M. Cecil, G.S. Salomons, and W.S. Ball Jr Irreversible brain creatine deficiency with elevated serum and urine creatine: a creatine transporter defect? Ann Neurol 49 3 2001 401 404
164. K.A. Hahn, G.S. Salomons, and D. Tackels-Horne X-linked mental retardation with seizures and carrier manifestations is caused by a mutation in the creatine-transporter gene (SLC6A8) located in Xq28 Am J Hum Genet 70 5 2002 1349 1356
165. C.B. Item, S. Stockler-Ipsiroglu, and C. Stromberger Arginine:glycine amidinotransferase deficiency: the third inborn error of creatine metabolism in humans Am J Hum Genet 69 5 2001 1127 1133
166. V. Leuzzi, M.C. Bianchi, and M. Tosetti Brain creatine depletion: guanidinoacetate methyltransferase deficiency (improving with creatine supplementation) Neurology 55 9 2000 1407 1409
167. M.S. van der Knaap, N.M. Verhoeven, and P. Maaswinkel-Mooij Mental retardation and behavioral problems as presenting signs of a creatine synthesis defect Ann Neurol 47 4 2000 540 543
168. A. Schulze, T. Hess, and R. Wevers Creatine deficiency syndrome caused by guanidinoacetate methyltransferase deficiency: diagnostic tools for a new inborn error of metabolism J Pediatr 131 4 1997 626 631
169. S. Stockler, U. Holzbach, and F. Hanefeld Creatine deficiency in the brain: a new, treatable inborn error of metabolism Pediatr Res 36 3 1994 409 413
170. T.J. deGrauw, G.S. Salomons, and K.M. Cecil Congenital creatine transporter deficiency Neuropediatrics 33 5 2002 232 238
171. E.H. Rosenberg, L.S. Almeida, and T. Kleefstra High prevalence of SLC6A8 deficiency in X-linked mental retardation Am J Hum Genet 75 1 2004 97 105